In monogenic diseases, the presence of several sequence variations in the same allele may complicate our understanding of genotype-phenotype relationships. We described new alterations identified in a cystic fibrosis (CF) patient harboring a 48C4G promoter sequence variation associated in cis of a 3532AC4GTA mutation and in trans with the F508del mutation. Functional analyses including in vitro experiments confirmed the deleterious effect of the 3532GTA frameshift mutation through the creation of a premature termination codon. The analyses also revealed that the 48G promoter variant has a negative effect on both transcription and mRNA level, thus demonstrating the importance of analyzing all mutations or sequence variations with potential impact on CF transmembrane conductance regulator processing, even when the two known disease-causing mutations have already been detected. Our results emphasize the need to perform, wherever possible, functional studies that may greatly assist the interpretation of the disease-causing potential of rare mutation-associated sequence variations.
INTRODUCTION
Cystic fibrosis (CF, MIM# 219700) is the most common lethal autosomal recessive disease affecting the Caucasian population, with an average prevalence of 1 in 3000 births. Birth prevalence varies from country to country and with ethnic background. 1 Although in its classical form, CF affects the physiology of several organs including the pancreas and the gastrointestinal and reproductive tracts, the morbidity is mainly due to pulmonary defects. 2 It is caused by mutations in the CF transmembrane conductance regulator (CFTR; MIM# 602421) gene, for which over 1850 sequence variations have been reported to date (http://www.genet.sickkids.on.ca/cftr/). The pathogenicity of several types of mutations such as nonsense, frameshift and splicing mutations are obvious, whereas the interpretation of the molecular consequences of others, such as silent mutations 3, 4 or those identified in non-coding regions, 5, 6 is arduous. In addition, the CFTR gene is characterized by the presence of a number of complex alleles, that is, at least two mutations in cis on the same chromosome that generally hinder the establishment of genotype-phenotype correlations. Mutations found in cis can modulate the effect of the principle mutation. The mutation R117H occurring in cis with the 5-thymidine (5T) tract variant in intron 8 generally results in pancreatic sufficient CF and as such, is considered as a mild mutation, whereas R117H in cis with the 7T is mainly considered as a CFTR-related disease-associated mutation with low penetrance. 7 Complex alleles may also involve alterations in the CFTR promoter region, as is the case for the (À102T4A;S549R)+(F508del) genotype for which the promoter sequence variation is associated with an increase in CFTR expression and a moderate clinical phenotype. 8 Here we report the functional analysis of a promoter variant associated in cis with a frameshift mutation (48C4G;3532AC4 GTA)+(F508del) identified in a patient with a classic form of CF as characterized by a positive sweat test, pulmonary symptoms, digestive manifestations and pancreatic insufficiency. The two alterations 48C4G and 3532AC4GTA are rare, as they have been identified in only one patient and none have been found to occur alone elsewhere. In our continuing efforts to assist in the interpretation of uncharacterized mutations, we assessed the contribution of each alteration towards the disease phenotype. Although the molecular defect induced by the 3532AC4GTA mutation (frameshift mutation) seems clear, we also evaluated whether the 48C4G promoter sequence variation modulates the effect of the 3532AC4GTA mutation.
MATERIALS AND METHODS

Nomenclature of mutations
For convenience to readers, we used legacy nomenclature as previously reported to the International Consortium Mutation Database (http://www.genet.sickkids. on.ca/cftr/). According to the Human Genome Variation Society nomenclature, the two described alterations 48C4G and 3532AC4GTA correspond to c.-85C4G and c.3400_3401delACinsGTA, respectively (GenBank NM_000492.3), where nucleotide number 1 corresponds to the A of the ATG translation initiation codon (previously the A of the ATG was numbered 133).
Plasmid constructs
To study the impact of the mutations, several CFTR constructions were created by direct mutagenesis (QuickChange II site directed mutagenesis kit, Agilent, Massy, France). The 48C4G sequence variation was introduced either in the CFTR promoter upstream of the Luciferase cDNA (pGL3b vector) or in the CFTR promoter upstream of the wild-type (WT) CFTR cDNA (pcDNA3-1 vector). The 3532AC4GTA was introduced in the CFTR cDNA under the control of either the CFTR promoter (WT or altered) or the CMV promoter in the pcDNA3-1 vector. The 3532AC4GTA was also introduced in a pSPL3-hybrid minigene containing WT CFTR exon 18 and flanking introns (150 bp).
All constructs were verified by sequencing. All the oligonucleotides used for generating the constructs are available on demand.
Transfection assays
The A549 pulmonary epithelial cell line was grown in DMEM/F12, and the Cos7 simian fibroblast cell line in DMEM, at 37 1C under 5% CO 2 . Each medium was completed with 5% SVF (Eurobio, Courtaboeuf, France), 1% Ultroser G (Pall, Saint Germain en Laye, France), 1% antibiotics (Invitrogen, Villebon sur Yvette, France) and 1% L-glutamine (Invitrogen). All transient transfections were realized with Polyfect (Qiagen, Courtaboeuf, France) in 6-well plates (BD falcon, Le Pont de Claix, France), with 1500 ng of indicated vector. For the reporter assay, cells were transfected in 96-well plates (BD falcon) using Fugene6 (Roche Applied Science, Meylan, France), with 60 ng of indicated reporter vector and 6 ng of pRL-SV40 (Renilla Luciferase) to normalize for transfection efficiency. Samples were harvested 48 h after transfection. A stable A549 cell line, containing WT or 48G-altered CFTR promoter was generated as previously described. 6 
Protein truncation test
In the first step, the CFTR fragment of interest was amplified from CFTR cDNA, using specific primers with the addition of the T7 promoter at the 5¢-end. 9 To generate WT and mutated peptides encompassing the 3532 position labeled with 35 S-methionine, we used the TNT T7 Quick Coupled Transcription/Translation System (Promega, Charbonnieres, France). Produced peptides were then separated by migration on a 12% denaturing acrylamide gel. After fixation and amplification, the signal was exposed on a Maximum Resolution film (Kodak, VWR, Pessac, France) during 12 h. Molecular weights were calculated with compute pl/Mw in ExPASy tools (Expasy Bioinformatics Resource portal, 'Compute pl/Mw tool' , http://web.expasy.org/compute_pi/).
Western blot
Whole protein extracts were directly collected in Laemmli buffer and sonicated before their loading on a 7% SDS-polyacrylamide gel. After migration, proteins were transferred onto a PVDF membrane (Westran Clear Signal, Whatman, Dominique Dutscher, Issy les Moulineaux, France), which was blocked with 5% skimmed milk in PBS-Tween for 1 h. Membranes were incubated overnight with anti-CFTR primary antibody (1:400, clone MM13-4 recognizing an N-terminus epitope, Millipore, Molsheim, France) or anti-Lamin A/C primary antibody (1:10000, Upstate, Millipore). After 1h of incubation with the anti-mouse secondary antibody, proteins were revealed with Immobilon Western Chemiluminescent HRP Substrate (Millipore) on a chemiluminescence detection film (Kodak).
Quantification of transcript level
Total mRNAs were purified with RNeasy plus Mini Kit (Qiagen) as recommended by the manufacturer. Genomic DNA was removed with DNase I amplification grade (Invitrogen). After treatment with RNasin (Promega), RT-PCR was performed on 1 mg of RNA with random primers and MML-V reverse transcriptase (Invitrogen). Quantitative PCR was realized with 1:50 diluted cDNA and amplified with the LightCycler 480 SYBR Green I Master (Roche Applied Science). CFTR cDNA was quantified and normalized by the quantification of GAPDH and b-actin housekeeping genes. Controls with no template or reverse transcriptase were also included. All PCR reactions were performed in triplicate in at least three independent experiments.
Minigene assay
Total mRNA extraction and RT-PCR were performed as described above for the quantification of transcript level. PCR was then performed using specific primers of pSPL3 plasmid and PCR Master Mix (Promega). Fragments were separated on a 1.5% agarose gel.
Reporter assay
The experiment was performed as previously described. 6 Firefly and Renilla Luciferase activities were measured 48 h after transfection by the DualLuciferase Reporter Assay System (Promega) according to the manufacturer's recommendations. Luciferase activities are representative of at least three independent experiments, with each construct tested in triplicate per experiment.
Quantitative chromatin immunoprecipitation assays (Q-ChIP)
Q-ChIP was performed as previously described, except for minor modifications. 6 Purified crosslinked chromatin was immunoprecipitated using 3 mg of anti-E2F, anti-MZF1 (myeloid zinc finger 1) or anti-Sp1 (specific protein 1) antibodies. As a control for non-specific binding of DNA, 3 mg of anti-HA, anti-goat or anti-mouse antibodies were used. All antibodies were obtained from Santa Cruz, Clinisciences (Montrouge, France), except for anti-HA, which was bought from Roche Applied Science. Input and immunoprecipitated DNAs were analyzed after their amplification on the LightCycler 480 real-time PCR system using the LightCycler 480 Probes Master, specific primers for the CFTR minimal promoter region encompassing the 48C4G sequence variation and probe #62 (Roche Applied Science). All PCR reactions were performed in triplicate. Experiments were performed at least three times and expressed relative to the input signal and to non-specific immunoprecipitated chromatin.
Statistical analyses
Data are expressed as the mean±SE. Paired comparisons were made using Student's t-test with InStat (GraphPad Software, version 3.0, Instat 3 folder, San Diego, CA, USA). Data were considered statistically significant at Po0.05 and extremely significant at Po0.0001.
RESULTS
Confirmation of the deleterious effect of the 3532AC4GTA frameshift mutation
We firstly hypothesized that the probable change in the open reading frame induced by the 3532GTA frameshift mutation generates a premature termination codon (PTC; Figure 1a) . We therefore performed a protein truncation test (PTT) by transcribing and translating in vitro the WT and mutated CFTR fragments. Results of electrophoresis showed a shift in the molecular weight of the synthesized peptides between CFTR-WT and CFTR-3532GTA conditions (Figure 1b) . The presence of a band with the expected molecular weight confirmed the creation of a PTC, 21 codons after the mutation, at the end of the last transmembrane segment.
To investigate further the several additional bands in the CFTR-3532GTA compared with the WT conditions revealed by our PTT, we assessed the effect of the 3532GTA mutation on CFTR maturation by western blot. Total proteins from cells transfected with an expression vector containing WT or mutated CFTR cDNA, downstream of the CMV promoter, were used for immunoblot assay. Total proteins from cells transfected with the construction containing WT CFTR cDNA resulted in typical bands including band C (mature, fully glycosylated protein, 170 kDa) and band B (immature, core-glycosylated protein, 140 kDa; Figure 1c) . As a control, we used the F508del mutation, known to induce protein misconformation and in turn, its premature degradation. No bands were detected, however, for the 3532GTA mutation as in the non-transfected condition, whereas protein was present, as confirmed using anti-Lamin A/C primary antibody. The mutated sequence therefore prevents protein synthesis, suggesting that transcripts bearing this PTC are potential targets for degradation through nonsense-mediated mRNA decay (NMD) and/or for exon skipping through nonsense-associated alternative splicing (NAS).
We next assessed the impact of the 3532GTA allele on the mRNA level or splicing process. Evaluation of mRNA amounts revealed that the 3532GTA mutation induces a decrease in CFTR transcript levels of more than 80%, compared with the WT condition in Cos-7 cells (Figure 1d ). The same results were obtained in A549 lung-specific cells (data not shown). Because this frameshift mutation might also produce both correctly and aberrantly spliced mRNA, we used a Promoter variant in the CFTR gene V Viart et al minigene assay to investigate whether the second control mechanism NAS could account for the observed inhibited synthesis. Hybrid minigene assay showed no difference between WT and mutated contexts ( Figure 1e ). As alternative splicing events have been proposed to differ between cell lines, 10 we verified that the same results were obtained in the other tested cell line A549 (data not shown). These results indicate that degradation of the transcript bearing the PTC in exon 18 is the result of NMD rather than NAS.
Characterization of the pathogenicity of the 48C4G promoter sequence variation To evaluate the effect of the 48G variant on transcriptional regulation, we performed a reporter assay. Luciferase activity, reflecting CFTR promoter control, indicated a decrease of about 40% in the 48G variant context compared with WT (Figure 2a) . We next assessed differences in CFTR mRNA amounts and found that the 48G allele induces a decrease of 75% in the CFTR transcript level when compared with the WT (Figure 2b ). These results suggest that the 48G promoter variant, in addition to its deleterious effect on transcription, may also disrupt the stability of the CFTR transcript. When associated in cis of the 3532GTA frameshift mutation, the 48G variant did not, however, increase the impact of 3532GTA alone on the mRNA level. Finally, we investigated which regulatory motifs, encompassing the 48C4G promoter sequence variation, were involved. Bioinformatics analyses predicted a change in binding capability of E2F, MZF1 and Sp1 transcription factors. We therefore performed Q-ChIP on WT or sequence-varied promoters, using specific anti-E2F, anti-MZF1 and anti-Sp1 antibodies. Results show that none of the three transcription 
DISCUSSION
Here we have described the contribution of each alteration (48C4G and 3532AC4GTA) to CFTR function. The creation of a PTC with the 3532GTA frameshift mutation has been confirmed using PTT assay. This mutation was shown to have a deleterious effect at both the mRNA and protein levels with results, suggesting the involvement of NMD in the recognition and degradation of aberrant transcripts. Although no band C was observed by western blot, indicating 100% degradation, residual CFTR mRNA was obtained. Previous studies have shown the concomitant nature of the translation and folding of CFTR. 11, 12 Our data suggest the role of an additional quality control mechanism that rapidly directs the elimination of the truncated protein (lacking NBD2) by ER-quality control systems. We next explored the functional impact of the 48C4G sequence variation found in the promoter in cis of the frameshift mutation. Study of the 48G variant shows its deleterious effect at the transcriptional and mRNA levels. This outcome could be, in part, explained by the higher affinity of the altered sequence for the three transcription factors E2F, MZF1 and Sp1. MZF1 is well known for its role in Promoter variant in the CFTR gene V Viart et al regulating cell proliferation, 13 but along with Sp1, it is also involved in regulating the expression of the human MUC1 gene, expressed in several epithelial tissues. 14 Furthermore, MZF1 has previously been identified as a putative inhibitor of the Cftr gene, through its binding in the À834 to À524 region of the mouse promoter. 15 Here we have shown that MZF1 only binds to the altered CFTR allele (48G), suggesting its partial role in decreasing promoter activity. E2F transcription factors are largely involved in cell cycle regulation, 16, 17 and along with MZF1, regulate genes that are developmentally regulated during cystogenesis. 18 Moreover, E2F and Sp1 can control the initiation of transcription in TATA-less promoters 19, 20 through their interaction with other proteins. For instance, E2F could superactivate Sp1-dependant transcription in DHFR TATA-less promoter. 21 Transcription factors, through their binding to regulatory regions, either activate or repress the transcription of their target genes by promoting or inhibiting the recruitment of RNA polymerase II, through TSS use. Indeed, E2F and Sp1 have been shown to interact with several proteins of the general transcription machinery, such as TFIIH and TFIID. [22] [23] [24] [25] These data suggest that the binding of these factors putatively modifies the use of the major TSS essential for CFTR transcription during lung development. 26, 27 The identification of alterations in non-coding regions and the determination of the impact of each allele component have several important consequences for recessive disorders such as CF. They permit a better understanding of the complex genotype-phenotype relationships and the opportunity to offer personalized genetic counseling or adapted therapy. These data reinforce the necessity to screen, wherever possible, for additional alterations even when two allelic mutations known to be disease causing are found, and especially when a discrepancy between phenotype and genotype is observed.
